Transcatheter aortic valve replacement in heart failure.
Aortic stenosis
Ejection fraction
Heart failure
Transcatheter aortic valve intervention
Transcatheter aortic valve replacement
Journal
European journal of heart failure
ISSN: 1879-0844
Titre abrégé: Eur J Heart Fail
Pays: England
ID NLM: 100887595
Informations de publication
Date de publication:
31 Jan 2024
31 Jan 2024
Historique:
revised:
06
01
2024
received:
27
03
2023
accepted:
17
01
2024
medline:
1
2
2024
pubmed:
1
2
2024
entrez:
1
2
2024
Statut:
aheadofprint
Résumé
Patients with severe aortic stenosis (AS) may develop heart failure (HF), the presence of which has traditionally been deemed as a final stage in AS progression with poor outcomes. The use of transcatheter aortic valve replacement (TAVR) has become the preferred therapy for most patients with AS and concomitant HF. With its instant afterload reduction, TAVR offers patients with HF significant haemodynamic benefits, with corresponding changes in left ventricular structure and improved mortality and quality of life. The prognostic covariates and optimal timing of TAVR in patients with less than severe AS remain unclear. The purpose of this review is to describe the association between TAVR and outcomes in patients with HF, particularly in the setting of left ventricular systolic dysfunction, acute HF, and right ventricular systolic dysfunction, and to highlight areas for future research.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 European Society of Cardiology.
Références
Ross J, Braunwald E. Aortic stenosis. Circulation 1968;38:61-67. https://doi.org/10.1161/01.CIR.38.1S5.V-61
Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP, Gentile F, et al. 2020 ACC/AHA Guideline for the management of patients with valvular heart disease: Executive summary: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2021;77:450-500. https://doi.org/10.1016/j.jacc.2020.11.035
Généreux P, Pibarot P, Redfors B, Mack MJ, Makkar RR, Jaber WA, et al. Staging classification of aortic stenosis based on the extent of cardiac damage. Eur Heart J 2017;38:3351-3358. https://doi.org/10.1093/eurheartj/ehx381
Biner S, Birati EY, Topilsky Y, Steinvil A, Ben Assa E, Sadeh B, et al. Outcome of transcatheter aortic valve implantation in patients with low-gradient severe aortic stenosis and preserved left ventricular ejection fraction. Am J Cardiol 2014;113:348-354. https://doi.org/10.1016/j.amjcard.2013.08.048
Baron SJ, Arnold SV, Herrmann HC, Holmes DR, Szeto WY, Allen KB, et al. Impact of ejection fraction and aortic valve gradient on outcomes of transcatheter aortic valve replacement. J Am Coll Cardiol 2016;67:2349-2358. https://doi.org/10.1016/j.jacc.2016.03.514
Durand E, Doutriaux M, Bettinger N, Tron C, Fauvel C, Bauer F, et al. Incidence, prognostic impact, and predictive factors of readmission for heart failure after transcatheter aortic valve replacement. JACC Cardiovasc Interv 2017;10:2426-2436. https://doi.org/10.1016/j.jcin.2017.09.010
Barbash IM, Minha S, Ben-Dor I, Dvir D, Magalhaes MA, Torguson R, et al. Relation of preprocedural assessment of myocardial contractility reserve on outcomes of aortic stenosis patients with impaired left ventricular function undergoing transcatheter aortic valve implantation. Am J Cardiol 2014;113:1536-1542. https://doi.org/10.1016/j.amjcard.2014.01.433
Furer A, Chen S, Redfors B, Elmariah S, Pibarot P, Herrmann HC, et al. Effect of baseline left ventricular ejection fraction on 2-year outcomes after transcatheter aortic valve replacement: Analysis of the PARTNER 2 trials. Circ Heart Fail 2019;12:e005809. https://doi.org/10.1161/CIRCHEARTFAILURE.118.005809
Ribeiro HB, Lerakis S, Gilard M, Cavalcante JL, Makkar R, Herrmann HC, et al. Transcatheter aortic valve replacement in patients with low-flow, low-gradient aortic stenosis: The TOPAS-TAVI registry. J Am Coll Cardiol 2018;71:1297-1308. https://doi.org/10.1016/j.jacc.2018.01.054
O'Sullivan CJ, Stortecky S, Bütikofer A, Heg D, Zanchin T, Huber C, et al. Impact of mitral regurgitation on clinical outcomes of patients with low-ejection fraction, low-gradient severe aortic stenosis undergoing transcatheter aortic valve implantation. Circ Cardiovasc Interv 2015;8:e001895. https://doi.org/10.1161/CIRCINTERVENTIONS.114.001895
Ludwig S, Goßling A, Seiffert M, Westermann D, Sinning JM, Sugiura A, et al. Risk prediction in patients with low-flow, low-gradient aortic stenosis and reduced ejection fraction undergoing TAVI. Open Heart 2022;9:e001912. https://doi.org/10.1136/openhrt-2021-001912
Elmariah S, Fearon WF, Inglessis I, Vlahakes GJ, Lindman BR, Alu MC, et al.; PARTNER Trial Investigators and PARTNER Publications Office. Transapical transcatheter aortic valve replacement is associated with increased cardiac mortality in patients with left ventricular dysfunction: Insights from the PARTNER I trial. JACC Cardiovasc Interv 2017;10:2414-2422. https://doi.org/10.1016/j.jcin.2017.09.023
Amer MR, Mosleh W, Memon S, Joshi S, Sullivan B, Sharkawi M, et al. Comparison of benefit of transcatheter aortic valve implantation in patients with low gradient versus high gradient aortic stenosis and left ventricular dysfunction. Am J Cardiol 2020;125:1543-1549. https://doi.org/10.1016/j.amjcard.2020.02.019
Carabello BA. Where do low-gradient, low-EF AS patients come from?: Maybe they're born that way. J Am Coll Cardiol 2018;71:1322-1324. https://doi.org/10.1016/j.jacc.2018.01.041
Carabello BA, Green LH, Grossman W, Cohn LH, Koster JK, Collins JJJ. Hemodynamic determinants of prognosis of aortic valve replacement in critical aortic stenosis and advanced congestive heart failure. Circulation 1980;62:42-48. https://doi.org/10.1161/01.cir.62.1.42
O'Sullivan CJ, Stortecky S, Heg D, Pilgrim T, Hosek N, Buellesfeld L, et al. Clinical outcomes of patients with low-flow, low-gradient, severe aortic stenosis and either preserved or reduced ejection fraction undergoing transcatheter aortic valve implantation. Eur Heart J 2013;34:3437-3450. https://doi.org/10.1093/eurheartj/eht408
Ito S, Miranda WR, Nkomo VT, Connolly HM, Pislaru SV, Greason KL, et al. Reduced left ventricular ejection fraction in patients with aortic stenosis. J Am Coll Cardiol 2018;71:1313-1321. https://doi.org/10.1016/j.jacc.2018.01.045
Angelillis M, Giannini C, De Carlo M, Adamo M, Nardi M, Colombo A, et al. Prognostic significance of change in the left ventricular ejection fraction after transcatheter aortic valve implantation in patients with severe aortic stenosis and left ventricular dysfunction. Am J Cardiol 2017;120:1639-1647. https://doi.org/10.1016/j.amjcard.2017.07.064
Kolte D, Bhardwaj B, Lu M, Alu MC, Passeri JJ, Inglessis I, et al. Association between early left ventricular ejection fraction improvement after transcatheter aortic valve replacement and 5-year clinical outcomes. JAMA Cardiol 2022;7:934-944. https://doi.org/10.1001/jamacardio.2022.2222
Jeong YJ, Ahn JM, Kang DY, Park H, Ko E, Kim HJ, et al. Incidence, predictors, and prognostic impact of immediate improvement in left ventricular systolic function after transcatheter aortic valve implantation. Am J Cardiol 2021;152:99-105. https://doi.org/10.1016/j.amjcard.2021.04.037
Buchanan KD, Rogers T, Steinvil A, Koifman E, Xu L, Torguson R, et al. Role of contractile reserve as a predictor of mortality in low-flow, low-gradient severe aortic stenosis following transcatheter aortic valve replacement. Catheter Cardiovasc Interv 2019;93:707-712. https://doi.org/10.1002/ccd.27914
Maes F, Lerakis S, Barbosa Ribeiro H, Gilard M, Cavalcante JL, Makkar R, et al. Outcomes from transcatheter aortic valve replacement in patients with low-flow, low-gradient aortic stenosis and left ventricular ejection fraction less than 30%: A substudy from the TOPAS-TAVI registry. JAMA Cardiol 2019;4:64-70. https://doi.org/10.1001/jamacardio.2018.4320
Bavishi C, Trivedi V, Sellke FW, Gordon PC, Abbott JD. Myocardial contractile reserve and mortality in patients with severe aortic stenosis with impaired left ventricular function who underwent transcatheter aortic valve implantation. Am J Cardiol 2021;141:150-152. https://doi.org/10.1016/j.amjcard.2020.11.023
van Gils L, Clavel MA, Vollema EM, Hahn RT, Spitzer E, Delgado V, et al. Prognostic implications of moderate aortic stenosis in patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2017;69:2383-2392. https://doi.org/10.1016/j.jacc.2017.03.023
Jean G, Van Mieghem NM, Gegenava T, van Gils L, Bernard J, Geleijnse ML, et al. Moderate aortic stenosis in patients with heart failure and reduced ejection fraction. J Am Coll Cardiol 2021;77:2796-2803. https://doi.org/10.1016/j.jacc.2021.04.014
Ludwig S, Schofer N, Abdel-Wahab M, Urena M, Jean G, Renker M, et al. Transcatheter aortic valve replacement in patients with reduced ejection fraction and nonsevere aortic stenosis. Circ Cardiovasc Interv 2023;16:e012768. https://doi.org/10.1161/CIRCINTERVENTIONS.122.012768
Ahmed A, Alsidawi S, Bae R, Cavalcante J, Fukui M, Gössl M, et al. Changes in quality of life in patients with low-flow aortic stenosis undergoing transcatheter aortic valve replacement. Catheter Cardiovasc Interv 2020;96:972-978. https://doi.org/10.1002/ccd.28805
Wagener M, Reuthebuch O, Heg D, Tüller D, Ferrari E, Grünenfelder J, et al. Clinical outcomes in high-gradient, classical low-flow, low-gradient, and paradoxical low-flow, low-gradient aortic stenosis after transcatheter aortic valve implantation: A report from the SwissTAVI registry. J Am Heart Assoc 2023;12:e029489. https://doi.org/10.1161/JAHA.123.029489
Mosleh W, Amer MR, Ding Y, Megaly M, Mather JF, McMahon S, et al. Benefit of transcatheter aortic valve replacement in patients with paradoxical low-flow low-gradient versus high-gradient aortic stenosis and preserved left ventricular function. Circ Cardiovasc Interv 2021;14:e010042. https://doi.org/10.1161/CIRCINTERVENTIONS.120.010042
Popovic B, Molho A, Varlot J, Fay R, Metzdorf PA, Elfarra M, et al. Prognostic influence of acute decompensated heart failure in patients planned for transcatheter aortic valve implantation. Catheter Cardiovasc Interv 2020;96:E542-E551. https://doi.org/10.1002/ccd.28813
Tang L, Gössl M, Ahmed A, Garberich R, Bradley SM, Niikura H, et al. Contemporary reasons and clinical outcomes for patients with severe, symptomatic aortic stenosis not undergoing aortic valve replacement. Circ Cardiovasc Interv 2018;11:e007220. https://doi.org/10.1161/CIRCINTERVENTIONS.118.007220
Jalava MP, Laakso T, Virtanen M, Niemelä M, Ahvenvaara T, Tauriainen T, et al. Transcatheter and surgical aortic valve replacement in patients with recent acute heart failure. Ann Thorac Surg 2020;109:110-117. https://doi.org/10.1016/j.athoracsur.2019.05.044
Kaewkes D, Ochiai T, Flint N, Patel V, Patel J, Kim I, et al. Transcatheter aortic valve implantation in patients with severe aortic stenosis hospitalized with acute heart failure. Am J Cardiol 2021;144:100-110. https://doi.org/10.1016/j.amjcard.2020.12.046
Chen S, Redfors B, Crowley A, Ben-Yehuda O, Summers M, Hahn RT, et al. Impact of recent heart failure hospitalization on clinical outcomes in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement: An analysis from the PARTNER 2 trial and registries. Eur J Heart Fail 2020;22:1866-1874. https://doi.org/10.1002/ejhf.1841
Asgar AW, Ouzounian M, Adams C, Afilalo J, Fremes S, Lauck S, et al. 2019 Canadian Cardiovascular Society position statement for transcatheter aortic valve implantation. Can J Cardiol 2019;35:1437-1448. https://doi.org/10.1016/j.cjca.2019.08.011
Asami M, Stortecky S, Praz F, Lanz J, Räber L, Franzone A, et al. Prognostic value of right ventricular dysfunction on clinical outcomes after transcatheter aortic valve replacement. JACC Cardiovasc Imaging 2019;12:577-587. https://doi.org/10.1016/j.jcmg.2017.12.015
Durand E, Sacri C, Levesque T, Tron C, Barbe T, Hemery T, et al. Incidence, predictive factors, and prognostic impact of right ventricular dysfunction before transcatheter aortic valve implantation. Am J Cardiol 2021;161:63-69. https://doi.org/10.1016/j.amjcard.2021.08.068
Généreux P, Pibarot P, Redfors B, Bax JJ, Zhao Y, Makkar RR, et al. Evolution and prognostic impact of cardiac damage after aortic valve replacement. J Am Coll Cardiol 2022;80:783-800. https://doi.org/10.1016/j.jacc.2022.05.006
Grevious SN, Fernandes MF, Annor AK, Ibrahim M, Saint Croix GR, de Marchena E, et al. Prognostic assessment of right ventricular systolic dysfunction on post-transcatheter aortic valve replacement short-term outcomes: Systematic review and meta-analysis. J Am Heart Assoc 2020;9:e014463. https://doi.org/10.1161/JAHA.119.014463
Granot Y, Merdler I, Finkelstein A, Arbel Y, Banai S, Topilsky Y, et al. Prognostic implication of right ventricular dysfunction and tricuspid regurgitation following transcatheter aortic valve replacement. Catheter Cardiovasc Interv 2021;98:E758-E767. https://doi.org/10.1002/ccd.29639
Tarantini G, Tang G, Nai Fovino L, Blackman D, Van Mieghem NM, Kim WK, et al. Management of coronary artery disease in patients undergoing transcatheter aortic valve implantation. A clinical consensus statement from the European Association of Percutaneous Cardiovascular Interventions in collaboration with the ESC Working Group on Cardiovascular Surgery. EuroIntervention 2023;19:37-52. https://doi.org/10.4244/EIJ-D-22-00958
Costa G, Pilgrim T, Amat Santos IJ, De Backer O, Kim WK, Barbosa Ribeiro H, et al.; REVASC-TAVI Registry. Management of myocardial revascularization in patients with stable coronary artery disease undergoing transcatheter aortic valve implantation. Circ Cardiovasc Interv 2022;15:e012417. https://doi.org/10.1161/CIRCINTERVENTIONS.122.012417
Patterson T, Clayton T, Dodd M, Khawaja Z, Morice MC, Wilson K, et al.; ACTIVATION Trial Investigators. ACTIVATION (PercutAneous Coronary inTervention prIor to transcatheter aortic VAlve implantaTION): A randomized clinical trial. JACC Cardiovasc Interv 2021;14:1965-1974. https://doi.org/10.1016/j.jcin.2021.06.041
Webb JG, Mack MJ, White JM, Dvir D, Blanke P, Herrmann HC, et al. Transcatheter aortic valve implantation within degenerated aortic surgical bioprostheses: PARTNER 2 valve-in-valve registry. J Am Coll Cardiol 2017;69:2253-2262. https://doi.org/10.1016/j.jacc.2017.02.057
Hahn RT, Webb J, Pibarot P, Ternacle J, Herrmann HC, Suri RM, et al. 5-year follow-up from the PARTNER 2 aortic valve-in-valve registry for degenerated aortic surgical bioprostheses. JACC Cardiovasc Interv 2022;15:698-708. https://doi.org/10.1016/j.jcin.2022.02.014
Akodad M, Meilhac A, Lefèvre T, Cayla G, Lattuca B, Autissier C, et al. Hemodynamic performances and clinical outcomes in patients undergoing valve-in-valve versus native transcatheter aortic valve implantation. Am J Cardiol 2019;124:90-97. https://doi.org/10.1016/j.amjcard.2019.04.009
Castaño A, Narotsky DL, Hamid N, Khalique OK, Morgenstern R, DeLuca A, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J 2017;38:2879-2887. https://doi.org/10.1093/eurheartj/ehx350
Nitsche C, Scully PR, Patel KP, Kammerlander AA, Koschutnik M, Dona C, et al. Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis. J Am Coll Cardiol 2021;77:128-139. https://doi.org/10.1016/j.jacc.2020.11.006
Nitsche C, Aschauer S, Kammerlander AA, Schneider M, Poschner T, Duca F, et al. Light-chain and transthyretin cardiac amyloidosis in severe aortic stenosis: Prevalence, screening possibilities, and outcome. Eur J Heart Fail 2020;22:1852-1862. https://doi.org/10.1002/ejhf.1756
Shimoni S, Zikri M, Haberman D, Livschitz S, Tshori S, Fabricant Y, et al. Transthyretin cardiac amyloidosis in patients after TAVR: Clinical and echocardiographic findings and long term survival. ESC Heart Fail 2021;8:4549-4561. https://doi.org/10.1002/ehf2.13667
Truby LK, Garan AR, Givens RC, Wayda B, Takeda K, Yuzefpolskaya M, et al. Aortic insufficiency during contemporary left ventricular assist device support: Analysis of the INTERMACS registry. JACC Heart Fail 2018;6:951-960. https://doi.org/10.1016/j.jchf.2018.07.012
Soleimani B, Haouzi A, Manoskey A, Stephenson ER, El-Banayosy A, Pae WE. Development of aortic insufficiency in patients supported with continuous flow left ventricular assist devices. ASAIO J 2012;58:326-329. https://doi.org/10.1097/MAT.0b013e318251cfff
Danley MR, Lensing C, Eagle SS, Kingeter MA. Transcatheter aortic valve replacement in patients with left ventricular assist devices and aortic regurgitation-single institution retrospective analysis. J Cardiothorac Vasc Anesth 2022;36:2839-2840. https://doi.org/10.1053/j.jvca.2022.03.020
Pesarini G, Lunardi M, Piccoli A, Gottin L, Prati D, Ferrero V, et al. Effectiveness and safety of transcatheter aortic valve implantation in patients with pure aortic regurgitation and advanced heart failure. Am J Cardiol 2018;121:642-648. https://doi.org/10.1016/j.amjcard.2017.11.042
Dhillon AS, Jones BM, Hodson RW, Korngold EC. Transcatheter aortic valve replacement for severe aortic regurgitation in patients with a left ventricular assist device. J Invasive Cardiol 2022;34:E369-E373.
Urena M, Webb JG, Eltchaninoff H, Muñoz-García AJ, Bouleti C, Tamburino C, et al. Late cardiac death in patients undergoing transcatheter aortic valve replacement: Incidence and predictors of advanced heart failure and sudden cardiac death. J Am Coll Cardiol 2015;65:437-448. https://doi.org/10.1016/j.jacc.2014.11.027
Auffret V, Bakhti A, Leurent G, Bedossa M, Tomasi J, Belhaj Soulami R, et al. Determinants and impact of heart failure readmission following transcatheter aortic valve replacement. Circ Cardiovasc Interv 2020;13:e008959. https://doi.org/10.1161/CIRCINTERVENTIONS.120.008959
Nazzari H, Hawkins NM, Ezekowitz J, Lauck S, Ding L, Polderman J, et al. The relationship between heart-failure hospitalization and mortality in patients receiving transcatheter aortic valve replacement. Can J Cardiol 2019;35:413-421. https://doi.org/10.1016/j.cjca.2018.11.016
Theron A, Lavagna F, Gaubert G, Resseguier N, Porto A, Ferrara J, et al. Prosthesis-patient mismatch is an independent predictor of congestive heart failure after transcatheter aortic valve replacement. Arch Cardiovasc Dis 2021;114:504-514. https://doi.org/10.1016/j.acvd.2020.11.005
Carrabba N, Valenti R, Migliorini A, Marrani M, Cantini G, Parodi G, et al. Impact on left ventricular function and remodeling and on 1-year outcome in patients with left bundle branch block after transcatheter aortic valve implantation. Am J Cardiol 2015;116:125-131. https://doi.org/10.1016/j.amjcard.2015.03.054
Tzikas A, van Dalen BM, Van Mieghem NM, Gutierrez-Chico JL, Nuis RJ, Kauer F, et al. Frequency of conduction abnormalities after transcatheter aortic valve implantation with the Medtronic-CoreValve and the effect on left ventricular ejection fraction. Am J Cardiol 2011;107:285-289. https://doi.org/10.1016/j.amjcard.2010.09.015
Sammour Y, Krishnaswamy A, Kumar A, Puri R, Tarakji KG, Bazarbashi N, et al. Incidence, predictors, and implications of permanent pacemaker requirement after transcatheter aortic valve replacement. JACC Cardiovasc Interv 2021;14:115-134. https://doi.org/10.1016/j.jcin.2020.09.063
Pagnesi M, Kim WK, Baggio S, Scotti A, Barbanti M, De Marco F, et al. Incidence, predictors, and prognostic impact of new permanent pacemaker implantation after TAVR with self-expanding valves. JACC Cardiovasc Interv 2023;16:2004-2017. https://doi.org/10.1016/j.jcin.2023.05.020
Fadahunsi OO, Olowoyeye A, Ukaigwe A, Li Z, Vora AN, Vemulapalli S, et al. Incidence, predictors, and outcomes of permanent pacemaker implantation following transcatheter aortic valve replacement: Analysis from the U.S. Society of Thoracic Surgeons/American College of Cardiology TVT Registry. JACC Cardiovasc Interv 2016;9:2189-2199. https://doi.org/10.1016/j.jcin.2016.07.026
Chamandi C, Barbanti M, Munoz-Garcia A, Latib A, Nombela-Franco L, Gutiérrez-Ibanez E, et al. Long-term outcomes in patients with new permanent pacemaker implantation following transcatheter aortic valve replacement. JACC Cardiovasc Interv 2018;11:301-310. https://doi.org/10.1016/j.jcin.2017.10.032
Tsushima T, Al-Kindi S, Palma Dallan LA, Fares A, Yoon SH, Wheat HL, et al. Clinical impact of right ventricular pacing burden in patients with post-transcatheter aortic valve replacement permanent pacemaker implantation. Europace 2023;25:1441-1450. https://doi.org/10.1093/europace/euad025
Ochiai T, Yamanaka F, Shishido K, Moriyama N, Komatsu I, Yokoyama H, et al. Impact of high implantation of transcatheter aortic valve on subsequent conduction disturbances and coronary access. JACC Cardiovasc Interv 2023;16:1192-1204. https://doi.org/10.1016/j.jcin.2023.03.021
Arnold SV, Manandhar P, Vemulapalli S, Vekstein AM, Kosinski AS, Spertus JA, et al. Patient-reported vs. physician-estimated symptoms before and after transcatheter aortic valve replacement. Eur Heart J Qual Care Clin Outcomes 2022;8:161-168. https://doi.org/10.1093/ehjqcco/qcab078
Arnold SV, Spertus JA, Vemulapalli S, Li Z, Matsouaka RA, Baron SJ, et al. Quality-of-life outcomes after transcatheter aortic valve replacement in an unselected population: A report from the STS/ACC Transcatheter Valve Therapy Registry. JAMA Cardiol 2017;2:409-416. https://doi.org/10.1001/jamacardio.2016.5302
Osnabrugge RL, Arnold SV, Reynolds MR, Magnuson EA, Wang K, Gaudiani VA, et al.; CoreValve U.S. Trial Investigators. Health status after transcatheter aortic valve replacement in patients at extreme surgical risk: Results from the CoreValve U.S. trial. JACC Cardiovasc Interv 2015;8:315-323. https://doi.org/10.1016/j.jcin.2014.08.016
Arnold SV, Manandhar P, Vemulapalli S, Kosinski A, Desai ND, Bavaria JE, et al. Impact of short-term complications of transcatheter aortic valve replacement on longer-term outcomes: Results from the STS/ACC Transcatheter Valve Therapy Registry. Eur Heart J Qual Care Clin Outcomes 2021;7:208-213. https://doi.org/10.1093/ehjqcco/qcaa001
Phuong N, Solomon RJ, DeSarno MJ, LeWinter MM, Zimmer J, Dauerman HL. Acute kidney injury and renin-angiotensin system inhibition following transcatheter aortic valve replacement. J Invasive Cardiol 2021;33:E662-E669.
Chen S, Redfors B, Nazif T, Kirtane A, Crowley A, Ben-Yehuda O, et al. Impact of renin-angiotensin system inhibitors on clinical outcomes in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement: An analysis of from the PARTNER 2 trial and registries. Eur Heart J 2020;41:943-954. https://doi.org/10.1093/eurheartj/ehz769
Rodriguez-Gabella T, Catalá P, Muñoz-García AJ, Nombela-Franco L, Del Valle R, Gutiérrez E, et al. Renin-angiotensin system inhibition following transcatheter aortic valve replacement. J Am Coll Cardiol 2019;74:631-641. https://doi.org/10.1016/j.jacc.2019.05.055
Inohara T, Manandhar P, Kosinski AS, Matsouaka RA, Kohsaka S, Mentz RJ, et al. Association of renin-angiotensin inhibitor treatment with mortality and heart failure readmission in patients with transcatheter aortic valve replacement. JAMA 2018;320:2231-2241. https://doi.org/10.1001/jama.2018.18077
Ledwoch J, Olbrich I, Poch F, Thalmann R, Fellner C, Stundl A, et al. Dose-dependent effect of renin-angiotensin system blockade following transcatheter aortic valve replacement. Can J Cardiol 2021;37:443-449. https://doi.org/10.1016/j.cjca.2020.08.014
Sun Y, Li J, Li G, Fan R, Luo J. Impact of renin-angiotensin system inhibitors on outcomes after transcatheter aortic valve replacement: A meta-analysis. Catheter Cardiovasc Interv 2021;97:E88-E94. https://doi.org/10.1002/ccd.28899
Amat-Santos IJ, Catalá P, Diez Del Hoyo F, Fernandez-Diaz JA, Alonso-Briales JH, Del Trigo M, et al. Impact of renin-angiotensin system inhibitors on clinical outcomes and ventricular remodelling after transcatheter aortic valve implantation: Rationale and design of the RASTAVI randomised multicentre study. BMJ Open 2018;8:e020255. https://doi.org/10.1136/bmjopen-2017-020255
Liao YB, Xia C, Cheng Y, Li Q, Wei X, Ou Y, et al. Angiotensin-converting enzyme inhibitor for post-transcatheter aortic valve implantation patients: Study protocol for a multicenter randomized, open-label blinded endpoint control trial. Trials 2021;22:462. https://doi.org/10.1186/s13063-021-05411-5
Amat-Santos IJ, Sánchez-Luna JP, Abu-Assi E, Melendo-Viu M, Cruz-Gonzalez I, Nombela-Franco L, et al.; Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) Investigators. Rationale and design of the Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) randomized trial. Eur J Heart Fail 2022;24:581-588. https://doi.org/10.1002/ejhf.2370
Saito T, Yoshijima N, Hase H, Yashima F, Tsuruta H, Shimizu H, et al. Impact of beta blockers on patients undergoing transcatheter aortic valve replacement: The OCEAN-TAVI registry. Open Heart 2020;7:e001269. https://doi.org/10.1136/openhrt-2020-001269
Younis A, Orvin K, Nof E, Barabash IM, Segev A, Berkovitch A, et al. The effect of periprocedural beta blocker withdrawal on arrhythmic risk following transcatheter aortic valve replacement. Catheter Cardiovasc Interv 2019;93:1361-1366. https://doi.org/10.1002/ccd.28017
Beohar N, Whisenant B, Kirtane AJ, Leon MB, Tuzcu EM, Makkar R, et al. The relative performance characteristics of the logistic European System for Cardiac Operative Risk Evaluation score and the Society of Thoracic Surgeons score in the Placement of Aortic Transcatheter Valves trial. J Thorac Cardiovasc Surg 2014;148:2830-2837.e1. https://doi.org/10.1016/j.jtcvs.2014.04.006
Edwards FH, Cohen DJ, O'Brien SM, Peterson ED, Mack MJ, Shahian DM, et al.; Steering Committee of the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. Development and validation of a risk prediction model for in-hospital mortality after transcatheter aortic valve replacement. JAMA Cardiol 2016;1:46-52. https://doi.org/10.1001/jamacardio.2015.0326
Codner P, Malick W, Kouz R, Patel A, Chen CH, Terre J, et al. Mortality risk after transcatheter aortic valve implantation: Analysis of the predictive accuracy of the Transcatheter Valve Therapy registry risk assessment model. EuroIntervention 2018;14:e405-e412. https://doi.org/10.4244/EIJ-D-18-00032
Arsalan M, Weferling M, Hecker F, Filardo G, Kim WK, Pollock BD, et al. TAVI risk scoring using established versus new scoring systems: Role of the new STS/ACC model. EuroIntervention 2018;13:1520-1526. https://doi.org/10.4244/EIJ-D-17-00421
Lantelme P, Lacour T, Bisson A, Herbert J, Ivanes F, Bourguignon T, et al. Futility risk model for predicting outcome after transcatheter aortic valve implantation. Am J Cardiol 2020;130:100-107. https://doi.org/10.1016/j.amjcard.2020.05.043
Thourani VH, O'Brien SM, Kelly JJ, Cohen DJ, Peterson ED, Mack MJ, et al. Development and application of a risk prediction model for in-hospital stroke after transcatheter aortic valve replacement: A report from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. Ann Thorac Surg 2019;107:1097-1103. https://doi.org/10.1016/j.athoracsur.2018.11.013
Navarese EP, Zhang Z, Kubica J, Andreotti F, Farinaccio A, Bartorelli AL, et al.; a Joint Effort of the Italian and Polish Cardiac Interventional Societies. Development and validation of a practical model to identify patients at risk of bleeding after TAVR. JACC Cardiovasc Interv 2021;14:1196-1206. https://doi.org/10.1016/j.jcin.2021.03.024
Tsushima T, Nadeem F, Al-Kindi S, Clevenger JR, Bansal EJ, Wheat HL, et al. Risk prediction model for cardiac implantable electronic device implantation after transcatheter aortic valve replacement. JACC Clin Electrophysiol 2020;6:295-303. https://doi.org/10.1016/j.jacep.2019.10.020